The addition of galunisertib to gemcitabine demonstrated improved overall and progression-free survival in pancreatic cancer.
Anti-CD19 chimeric antigen receptor (CAR) T-cells were determined to be safe for further study in patients with refractory aggressive non-Hodgkin lymphoma.
Neoadjuvant ado-trastuzumab emtansine (T-DM1) combined with pertuzumab substantially improved pathologic complete response rates.
Monotherapy with labetuzumab govitecan is active in heavily pretreated patients with metastatic colorectal cancer (mCRC).
Entinostat may synergistically improve the therapeutic effect of high dose interleukin-2 (IL-2) in treatment-naïve clear cell renal cell carcinoma (RCC).
Crizotinib induces objective responses and long-lasting disease control in metastatic papillary renal cell carcinoma type 1 (PRCC1).
Most patients with progressive chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy harbor BTK and/or PLCG2 mutations.
Programmed death-ligand 1 (PD-L1) positivity is associated with improved efficacy with pembrolizumab in patients with advanced melanoma.
First-line therapy with pembrolizumab yielded frequent and durable response in patients with advanced Merkel cell carcinoma.
Nivolumab improved overall survival in patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
After 5 years of follow-up, 34% of patients with advanced melanoma who participated in a phase 1 clinical trial are still alive after receiving nivolumab treatment.
Short-term pre-operative treatment with palbociclib significantly reduced Ki67 in treatment-naïve patients with early-stage breast cancer.
The MammaPrint genetic test can reduce the use of adjuvant chemotherapy following surgery among patients with early-stage breast cancer.
High serum amyloid A (SAA) and low CXC chemokine ligand 4 (CXCL4) at time of initial diagnosis are associated with poorer prognosis in osteosarcoma.
Patients with early negativization of BRAF V600 in tumor-derived circulating cell-free DNA (cfDNA) have excellent prognosis.
Fibroblast growth factor receptor 1 (FGFR1) amplification and overexpression are common events in multiple subtypes of soft tissue sarcoma.
Adding bevacizumab to front-line chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab (PCR) may be safe and effective.
Single nucleotide polymorphism (SNP) IL17F-rs9463772 represents a prognostic marker of long-term survival in locally advanced rectal cancer.
KRAS mutation in cell-free DNA (cfDNA) may be associated with treatment response to gemcitabine plus cisplatin chemotherapy in pancreatic cancer.
Platelet counts at the time of initial diagnosis had prognostic value for patients with rectal adenocarcinoma receiving neoadjuvant treatment.
Bcl-2 family member (BIM) expression and phosphoinositide 3 kinase R1 (PIK3R1) might be candidate biomarkers for renal cell carcinoma (mRCC).
Serum fibroblast growth factor 21 (FGF21) is useful as a diagnostic and prognostic biomarker in patients with clear cell renal cell carcinoma (ccRCC).
Molecular pathways identified that may serve as potential biomarkers in prostate cancer treated with stereotactic body radiation therapy (SBRT).
Metformin, a widely used oral anti-diabetic drug, enhanced the anti-prostate cancer activity of abiraterone and enzalutamide.
Adding an XPO1 inhibitor, such as selinexor, to melphalan may significantly improve the treatment outcomes of patients with multiple myeloma.
BRCA1, AEG1 Expression Do Not Impact Outcomes in Patients With NSCLC Receiving Erlotinib, BevacizumabApril 14, 2016
BRCA1 and AEG1 mRNA expression levels do not significantly impact median progression-free survival in non-small cell lung cancer (NSCLC).
Treatment with a single epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can no longer be considered adequate.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
- Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer
- Rates of Adverse Events Similar Regardless of IMRT Boost Type